Fannin Innovation Studio

Program

"All companies in the Fannin portfolio are medical technology companies in the Texas Medical Center. Fannin Innovation Studio invests in these companies and works with them to take their ideas to market. In exchange for equity, the leaders of Fannin help co-found and manage the companies, and provide companies with working space, networking resources, and investment money. One of the three members of the leadership team manages each portfolio company. Fannin helps its portfolio companies gain grant money, secure licensing, seek mentorship, and move into the next stage of development."

[Fannin Website]

"Fannin’s model is to incubate its portfolio companies and provide shared management, thereby taking those costs off of the books of young biotech companies."

[Xconomy on Fanin and Acelerox]

• Note: Angela Shah has written multiple articles for Xconomy about Fannin and its startups.

Portfolio

• Accelerox
  • ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke and traumatic brain injury. The company’s proprietary class of molecules, termed PEG-HCCs, can be used to directly treat the symptoms of these diseases as well as to deliver chemotherapeutic drugs into tumors.
• ACF Pharmaceuticals
  • ACF PHARMACEUTICALS is a pre-clinical stage company testing novel molecules targeting the PGE2 pathway, which is important in cancer, fibrosis, inflammation and pain, in a unique partnership with a private chemical company and a research institution.
• Apaxis Medical
  • APAXIS MEDICAL is developing a proprietary left ventricular assist device (LVAD) “connector” designed to make LVAD implantation faster and more reliable. Apaxis aims to improve physician experience with LVAD implementation, thereby growing the market and encouraging earlier interventions. Its associated company, Apaxis Kit has developed a suite of proprietary surgical tools that are designed to enable less invasive, safer off-pump LVAD implantations.
• Brevitest Technologies
  • BREVITEST TECHNOLOGIES is developing a biomedical assay platform technology that could allow consumers, patients, caregivers, and others to more easily detect and quantify molecules of interest from a variety of sample types like blood, saliva, urine and water. This approach provides for a compact point-of-care diagnostics that is sensitive, specific and rapid. The BreviTest platform can be applied to a broad array of diagnostic tests, including those in emergency and non-emergency settings, allergen detection, home monitoring of chronic diseases as well as physiological conditions.
• Clearview App
  • CLEARVIEW APP is developing a patent-pending assay platform technology that could allow users to visualize and identify contaminants on a broad range of surfaces. ClearView has developed technology base on a low-cost proprietary hardware added on to devices such as smart phones combined with a downloadable app.
• Guidabot
  • GUIDABOT is developing robotic and imaging technologies to enable image-guided interventions (IGI) with real-time MRI (rtMRI) guidance. Interventions enabled by Guidabot’s patent pending technology will allow more efficient and safe tissue biopsy or delivery of brachytherapy seeds. Guidabot’s technology will enable a greater number of interventions to be performed by an imaging facility, thereby increasing throughput and associated revenue.
• NewHeart
  • NEWHEART DEVICES holds the patent on a continuous flow (pulseless) artificial heart comprised of paired ventricular assist devices (VADs). The technology, still in the early development stage and virtually entirely funded by federal grants, was featured on the March 2012 cover of Popular Science after a trial version was implanted in a Houston man where it maintained life for five weeks.
• Procyrion
  • VC funding
  • PROCYRION is developing a device that improves the treatment of heart failure. Deployed in the aorta using a catheter, the AortixTM is believed to represent one of the most minimally invasive heart failure devices currently in development, and its successful development could offer cardiologists a new way of treating the estimated 2.6 million U.S. patients who are no longer responding well to drug therapies for heart failure, a condition which costs $35 billion annually to treat in the U.S.
• Pulmotect
  • PULMOTECT is a clinical-stage pharmaceutical company developing PUL-042, a drug that stimulates the innate immune system in the lungs, which could provide short-term elevated capability to defend the body against inhaled pathogenic threats. While that application of technology is broad (and includes asthma, bioterror, pandemics and other indication), the Company’s initial clinical program is focused on patients at uniquely high risk for airborne infection, including leukemia patients enduring regimes of chemotherapy and organ transplant patients, who become immune-compromised as part of the transplant regime.

Leadership Team

• Leo Linbeck III: Chairman and Founder, CEO of Aquinas Companies, LLC
• Dr. Atul Varadhachary, MD, PhD: Managing Partner
• Mark Worscheh: CFO, Executive VP of Aquinas Companies, LLC

Contact

3900 Essex Lane, Suite 575 Houston, Texas 77027